Women and Men Age Differently—in More Ways Than Just Longevity

Nir Barzilai, M.D., says varying rates of protein level changes are among the biological differences in how men and women age. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein and an endocrinologist at Montefiore.


Fight the Coronavirus by Defending the Host

Nir Barzilai, M.D., co-authors an op-ed that calls for a national campaign to combat chronic disease and fund research on drugs that target age-related disease—measures that could help protect vulnerable populations from the ravages of COVID-19. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein and an endocrinologist at Montefiore.


To Fight COVID-19, Don't Neglect Immunity and Inflammation

Nir Barzilai, M.D., says vulnerability to COVID-19 increases at around age 55, but that older adults can slow or even reverse their declining immune defenses with an improved diet and exercise regimen. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.


In a Historically Old Presidential Field, Candidates Refuse to Release Health Records

Nir Barzilai, M.D., explains how age is a risk factor for many diseases, but notes a mix of other factors, including genetics and lifestyle, can extend the years one remains free of serious disease. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.


Scientists Harness AI to Reverse Aging in Billion-Dollar Industry

Nir Barzilai, M.D., describes his planned clinical trial that will study the effects of metformin, a drug used to treat diabetes, on aging. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair in Aging Research and director of the Institute for Aging Research at Einstein and an endocrinologist at Montefiore.


Patients Experiment With Prescription Drugs To Fight Aging

Despite the "off-label" use of some drugs, like metformin, to fight the effects of aging, Nir Barzilai, M.D., believes rigorous clinical trials are necessary to prove their efficacy and safety. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair in Aging Research and director of the Institute for Aging Research at Einstein and an endocrinologist at Montefiore.


Will You Really Need a Geriatrician When You’re 65?

Nir Barzilai, M.D., advises patients to consider their health conditions, mobility, level of frailty, and other factors—not simply chronological age—when deciding whether they should see a geriatrician. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair in Aging Research and director of the Institute for Aging Research at Einstein and an endocrinologist at Montefiore.


Could Drugs Delay the Diseases of Aging?

A series on aging features research by Dr. Nir Barzilai, and his planned clinical study on the effects of the drug metformin on age-related disease. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair in Aging Research and director of the Institute for Aging Research at Einstein.


Could 'longevity pill' help you live longer and healthier?

Maria Shriver interviews Nir Barzilai, M.D., about his planned clinical study on metformin, a common diabetes medication that may delay age-related disease. Dr. Barzilai is director of the Institute for Aging Research and holds the Ingeborg and Ira Leon Rennert Chair in Aging Research at Einstein.


Scientists Discover a Key to a Longer Life in Male DNA

Gil Atzmon, Ph.D., and Nir Barzilai, M.D. discuss their study on a common genetic mutation in men and its link to longevity. Dr. Atzmon is associate professor of medicine and of genetics. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.

More coverage on this story

Gizmodo
The Scientist


The New York Times interviews Nir Barzilai, M.D., on the development of self-driving cars to serve older adults. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.


The Washington Post interviews Nir Barzilai, M.D., about Donald Trump’s health, human aging, and questions about the factors affecting longevity and healthspan. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.


U.S. News & World Report interviews Ana Maria Cuervo, M.D., Ph.D., and Nir Barzilai, M.D., about their aging research.  Drs. Cuervo and Barzilai are co-directors of Einstein’s Institute for Aging Research.


The New York Times interviews Dr. Nir Barzilai, M.D., about his upcoming clinical trial to determine if an existing FDA-approved drug can extend health span. Dr. Barzilai and his collaborators at the American Federation for Aging Research will investigate if metformin, a cheap and commonly used medication to treat type 2 diabetes, can delay the onset of several age-related diseases. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.

More coverage on this story

The Washington Post


National Geographic highlights the leadership role Nir Barzilai, M.D., is taking in a clinical trial to determine if a common diabetes drug can delay aging. Dr. Barzilai notes that the goal of the Targeting Aging with Metformin (TAME) study is not to find the “fountain of youth,” but to extend the number of healthy, active years humans can enjoy. Dr. Barzilai is the Ingeborg and Ira Leon Rennert Chair of Aging Research and director of the Institute for Aging Research at Einstein.

More coverage on this story

Forbes
Fox News
PIX 11
National Post (Canada)
The Telegraph
Newsweek